A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemiaA recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia
Antibody fragments are promising constructing blocks for creating focused therapeutics, thus enhancing remedy efficacy whereas minimising off-target toxicity. Regardless of latest advances in focused therapeutics, sufferers with Philadelphia-like acute lymphoblastic leukemia